InaVein Announces Publication of Largest Patient Study

LEXINGTON, Mass. – May 15, 2009 -- InaVein, LLC announced today that the largest study to date on its TRIVEX System for the removal of extensive varicose veins will be published in the May/June 2009 issue of the peer-reviewed journal Annals of Vascular Surgery. Authored by Randall W. Franz, M.D. and Eric D. Knapp, D.O. from the Vascular and Vein Center at Grant Medical Center, Columbus, OH, the study of 339 patients over a six-year period reports a mean operative time of 19.7 minutes, no recurrences at 12 weeks post-op follow-up, and 99.7% of patients reporting a good outcome and satisfaction with the procedure.

About InaVein
InaVein, LLC is a privately held company engaged in the development, manufacture, marketing and commercialization of unique medical devices for the treatment of vein disease. The company’s flagship product, The TRIVEX™ System, is the first technology to provide surgeons with a minimally invasive technique to remove varicose veins safely and efficiently under direct vision. Since 2003, thousands of patients worldwide have been successfully treated using The TRIVEX System to completely remove their varicose veins. In addition, the company is developing other vascular products to assist clinicians in treating the full spectrum of conditions caused by peripheral venous disease.

For more information please contact:
InaVein
Michael McCartin
Vice President-Marketing and Sales
617.245.1965 ext. 1107